Obesity is attributable to the effects of genetic and environmental factors, and it affects human health. Accumulation of visceral fat, in particular, may play an important role in the pathogenesis of glucose intolerance, hyperlipidemia, and hypertension, and the accumulation of visceral fat is closely linked with atherosclerosis. Many genes are suspected to be associated with obesity, and recently the ß3-adrenergic receptor gene (ADRB3) has become the center of attention. In humans ADRB3 is predominantly expressed in visceral adipose tissue. It contains seven transmembrane domains and is coupled with G proteins. Stimulation of the ADRB3 by ß-adrenergic agonists has been demonstrated to activate adenylate cyclase, which increases the intracellular cyclic AMP level and leads to acceleration of lipid metabolism and thermogenesis.
In 1995, Pima Indians, an ethnic group with a very high prevalence of obesity and non-insulin-dependent diabetes mellitus (NIDDM), were found to have a high frequency of the Trp64Arg polymorphism due to the replacement of thymidine (T) by cytosine (C) at nucleotide position 190 in ADRB3, and those with the polymorphism were found to have early onset of NIDDM and a low resting metabolic rate. Subjects with the polymorphism in France have been found to have increased capacity to gain weight, and the polymorphism is associated with abdominal obesity in Finns and may cause insulin resistance and earlier onset of NIDDM in that population.

The polymorphism has been detected at an allelic frequency of about 0.20 in Japanese, which is lower than in Pima Indians (0.31) and higher than in Mexican-Americans (0.13), Blacks (0.12) and Whites (0.08) in the United States. The resting metabolic rate of obese Japanese women with the polymorphism is about 200 kcal/day lower than of those without the polymorphism, and women with the polymorphism have difficulty in losing weight. Moreover, the polymorphism has been found to be associated with visceral-fat obesity and insulin resistance syndrome, and it may be possible to use the polymorphism as a genetic marker for these syndromes. Other studies have also shown that the polymorphism is associated with obesity and insulin resistance.

A meta-analysis of the association between the polymorphism of ADRB3 and body mass index (BMI) in 31 studies demonstrated that subjects with the polymorphism had a BMI that averaged 0.30 (95% confidence interval [CI]=0.13-0.47) higher than those without the polymorphism.

Many studies have demonstrated that the polymorphism of ADRB3 is associated with obesity, but few studies have shown that it is possible to prevent or treat obesity and its complications in persons with the polymorphism. Therefore, to achieve tailor-made prevention or treatment based on genotype, including ADRB3, we investigated the interaction between energy intake and the polymorphism in ADRB3 in healthy Japanese men.

This study was approved by the Institutional Review Board (IRB) of Keio University School of Medicine, and was carried out in concordance with the principles of the Declaration of Helsinki. We explained this study by means of a written document to healthy Japanese men and women working for a company in Kanagawa prefecture and obtained written informed consent from 363 workers (male: 326, female: 37) to participate in the study, which included genotyping. The following surveys and genotyping for the polymorphism of ADRB3 were conducted in October and November 2003, and we obtained complete replies to the food frequency questionnaire (FFQ) from 337 (male: 295, female: 32) of the 363 workers, who were genotyped for the polymorphism of ADRB3. Allowing for the fact that the Japan Society for the Study of Obesity established different criteria for ‘obesity disease’ in men and women, and the report that men might have a higher risk of coronary heart disease than women due to the difference in body fat distribution, we performed the analysis focused on the 295 male workers.

Their mean age, waist circumference, and BMI (mean ± standard deviation) were 46.1 ± 11.5 years, 83.9 ± 9.3 cm, and 23.3 ± 3.3 kg/m², respectively. Height, weight, waist circumference, systolic and diastolic blood pressure, fasting plasma glucose level, and serum lipid levels were measured in all the subjects. A Body mass index (BMI) was calculated as weight (kg)/height² (m²). Obesity was defined as BMI 25+ kg/m² or waist circumference 85+ cm, based on the criteria for ‘obesity’ of the Japan Society for the Study of Obesity. In addition, information on the age, physical activity, smoking status, energy intake, and the protein, fat, and carbohydrate (PFC) ratio of all the subjects was obtained by means of a self-report questionnaire. The semi-quantitative food frequency questionnaire (FFQ), which was evaluated by comparing the FFQ with the 7-day dietary records of 66 subjects by Takahasi K, et al. 14, was used to calculate energy intake and PFC ratio. Takahasi K, et al. reported that the correlation coefficients between the FFQ and the 7-day dietary records for energy, protein, fat, and carbohydrate intake were 0.47 (p < 0.001), 0.42 (p < 0.001), 0.39 (p < 0.01), and 0.49 (p < 0.001), respectively.

Daily physical activity was calculated based on hours per day subjects engaged in each activity. The intensity of each activity was quantified by assigning metabolic equivalents (METs) to each activity. METs represent the ratio of energy expended during each specific activity to resting metabolic rate. The time spent in each activity was multiplied by the specific number of METs assigned to each activity, and the products were summed. The sum was defined as the daily physical activity (METs · minutes) of each subject.

The FFQ used in this study asked about the consumption of food items in 29 food groups during the previous one or two months. Basically, the subjects were asked to describe the quantities and frequencies of consumption of food items during breakfast, lunch, and dinner. Three portion size categories (small, medium, and large) were used to evaluate the quantities of consumption of food items. "Small" is half the size of "medium", and "large" is one and a half times the size of "medium". When the frequency of consumption of a food is less than once or twice a month, the subject is instructed to answer "never". The FFQ illustrated the food items of each food group in quantity equal to "medium", so as to evaluate the quantities of consumption correctly. When the frequency of consumption of a food was low, the subjects were asked to answer the quantity of consumed at one time and the frequency of consumption per week. Foods of this kind included sea vegetables, fruit, potatoes, butter, pickles, etc. The subjects were also asked to describe the quantity of consumption at one time and the frequency of consumption per week of alcoholic and non-alcoholic beverages. When the quantity of a unit of a food was almost identical among subjects, the subjects were asked to state only the frequency of consumption per week.
as the number of consumed units. Foods of this kind included rice, milk, egg, etc. Daily nutrient intake was calculated by multiplying the frequency of consumption of each food by the nutrient content of the portion size and summing the products for all foods items. The energy intake and PFC ratio of each subject were determined in this manner.

A peripheral blood specimen was collected from each subject, and genotyping for the polymorphism of ADRB3 was performed by polymerase chain reaction (PCR) and single nucleotide primer extension (SNuPE) assay with Ampdirect (Shimadzu Corporation, Kyoto, Japan), which eliminates the DNA extraction process and amplifies the genomic DNA directly from the whole blood.

A 367-bp fragment of the gene encompassing the polymorphism site was amplified by PCR using 5'-primer (5'TTC-CTTCTTTCCTACGGCCCGC)' and 3'-primer (5GCAGCCAGTGGC GGCCCCACGG). The PCR reactions were carried out in the PCR mixture containing 10 L of Ampdirect-G/C (Shimadzu Corporation, Kyoto, Japan), 10 L of Ampdirect Addition (Shimadzu Corporation, Kyoto, Japan), 4 L of dNTP mixture (TaKaRa Bio Inc., Shiga, Japan), 0.5 M of 5'-primer, 1.5 M of 3'-primer, 0.25 L of Taq DNA Polymerase (Promega Corporation, Wisconsin, USA), up to 50 L of distilled water, and 1.0 L of whole blood. The PCR consisted of preheating at 80 °C for 15 minutes; denaturation at 94 °C for 4.5 minutes; 40 cycles of denaturation at 94 °C for 30 seconds, annealing at 60 °C for 1 minute, and extension at 72 °C for 1 minute; a final extension at 72 °C for 7 minutes. The SNuPE assay was then performed. The SNuPE assay was based on the incorporation of a single fluorescent-labeled ddNTP, which was correctly paired with the template DNA and caused chain-termination, to the 3' terminus of a primer annealed next to the polymorphic site. The SNuPE primer (5'ATGGTCGAGTCTCAGGTTCC) was designed so that the primer ends immediately before the polymorphic site. The SNuPE reactions were carried out in the mixture; containing 2 L of PCR product, 4 L of SNuPE premix (ddATP, ddCTP, ddGTP, ddTTP, DNA polymerase), and 2 PM of SNuPE primer. The SNuPE consisted of 25 cycles of denaturation at 94 °C for 10 seconds, annealing at 53 °C for 5 seconds, and extension at 60 °C for 10 seconds. The products were analyzed with ABI 7700 (Applied Biosystems, California, USA).

For statistical analysis, Student's t-test was used to compare normally distributed variables between groups. Variables that were not normally distributed were log transformed. When the log transformations of the variables were effective, Student's t-test was used. When ineffective, the Wilcoxon rank-sum test was used. The 2 test was used to compare categorical variables. Multiple logistic regression analysis was performed on obesity defined as waist circumference 85+ cm, with presence of the polymorphism of ADRB3, age, smoking, and physical activity as variables.

Differences were assessed by two-sided tests, with an alpha level of 0.05. All statistical analyses were performed with Statistical Package for the Social Sciences* (SPSS) for Windows, version 11 software (SPSS Inc., Illinois, USA).

Genotyping for the Trp64Arg polymorphism of ADRB3 in the 295 healthy Japanese male subjects showed that 198 were homozygous for the wild-type allele (Trp/Trp), 94 were heterozygous for the variant allele (Arg/Trp), and 3 were homozygous for the variant allele (Arg/Arg) (allelic frequency=0.17). These results were in Hardy-Weinberg equilibrium and did not conflict with the results previously reported in another Japanese population (p=0.240).11

The main characteristics of the subjects are shown in Table 1. There were no significant differences between the subjects with and without the polymorphism with regard to age, height, weight, BMI, waist circumference, systolic or diastolic blood pressure, fasting plasma glucose, triglyceride, or HDL cholesterol levels, PFC ratio (fat, carbohydrate), energy intake, physical activity, or smoker/non-smoker ratio. The total cholesterol values and PFC ratio (protein) of the subjects with the polymorphism were significantly lower than the subjects without the polymorphism (p=0.016 and 0.026, respectively).

The subjects were classified into quartiles according to energy intake based on their replies to the FFQ. The mean waist circumference and BMI values in each quartile are shown in Table 2. There were no significant differences in waist circumference between the subjects in the 1st quartile and the subjects in the other quartiles. There was a significant difference in BMI between the subjects in the 1st quartile and in the 4th quartile (p=0.035), but not between the subjects in the 1st quartile and the subjects in the 2nd or the 3rd quartile. In addition, the trend test showed progressive increases in waist circumference and BMI in the quartiles that paralleled increased levels of energy intake (p=0.043 and 0.024, respectively).

We then divided each quartile into two groups according to presence of the polymorphism and calculated the ratio of the obese to the non-obese subjects in each group (Tables 3 and 4). When subjects with waist circumference 85+ cm were defined as obese (Table 3) in the 2nd quartile, the ratio of the group with the polymorphism was significantly lower than that of the group without the polymorphism (odds ratio [OR]=0.278, 95% CI=0.10-0.78), and in the 4th quartile, the ratio of the group with the polymorphism was significantly lower than that of the group without the polymorphism (OR=3.490, 95% CI=1.24-9.85). These results were in Hardy-Weinberg equilibrium and did not conflict with the results previously reported in another Japanese population (p=0.240).11

When subjects with BMI 25+ kg/m2 were defined as obese, no significant difference between the ratio of obese to non-obese subjects in the group with the polymorphism and the group without the polymorphism was seen in any of the quartile (Table 4).

The results of the multiple logistic regression analysis on obesity (defined as waist circumference 85+ cm) in the 4th quartile (total: 74, without polymorphism: 48, with polymorphism: 26) are shown in Table 5, in which the presence of ADRB3 polymorphism was determined in this manner.
Table 1. Clinical characteristics of the subjects, according to the ADRB3 polymorphism.

| ADRB3 genotype | All subjects | without polymorphism (Trp/Trp) | with polymorphism (Trp/Arg or Arg/Arg) | p value |
|----------------|--------------|---------------------------------|----------------------------------------|---------|
| n              | 295          | 198                             | 97                                     |         |
| Age (years)*   | 46.1 ± 11.5  | 46.5 ± 11.3                     | 45.3 ± 11.9                            | 0.300   |
| Height (cm)    | 168.6 ± 6.26 | 168.3 ± 6.19                    | 169.1 ± 6.41                           | 0.289   |
| Weight (kg)    | 66.3 ± 10.4  | 66.3 ± 10.3                     | 66.3 ± 10.6                            | 0.999   |
| Body mass index (kg/m²) | 23.3 ± 3.28 | 23.4 ± 3.20                     | 23.2 ± 3.47                            | 0.633   |
| Waist circumference (cm) | 83.9 ± 9.30 | 84.1 ± 9.19                     | 83.5 ± 9.57                            | 0.636   |
| Systolic blood pressure (mmHg) | 134.4 ± 18.0 | 134.0 ± 18.5                    | 135.2 ± 16.8                           | 0.582   |
| Diastolic blood pressure (mmHg) | 81.7 ± 12.7  | 81.4 ± 13.1                     | 82.3 ± 11.8                            | 0.576   |
| Fasting plasma glucose (mg/dL) | 100.2 ± 34.0 | 99.2 ± 31.8                     | 102.5 ± 38.5                           | 0.481   |
| Total cholesterol (mg/dL) | 206.9 ± 37.0 | 210.6 ± 35.8                    | 199.3 ± 38.6                           | 0.016   |
| Triglyceride (mg/dL)** | 131.9 ± 83.1 | 134.2 ± 86.1                    | 127.1 ± 76.6                           | 0.664   |
| HDL cholesterol (mg/dL) | 55.5 ± 14.0  | 55.5 ± 12.8                     | 55.4 ± 16.4                            | 0.976   |
| Protein, fat, and carbohydrate ratio (%) | | | | |
| Protein (%)    | 13.9 ± 2.39  | 14.1 ± 2.48                     | 13.5 ± 2.14                            | 0.026   |
| Fat (%)        | 27.6 ± 5.36  | 27.7 ± 5.48                     | 27.6 ± 5.13                            | 0.890   |
| Carbohydrate (%) | 58.5 ± 6.88  | 58.2 ± 7.06                     | 59.0 ± 6.51                            | 0.379   |
| Energy intake (kcal/day) | 1855.3 ± 485.0 | 1857.3 ± 509.2                 | 1851.3 ± 433.9                         | 0.920   |
| Physical activity (METs * minutes) | 2457.0 ± 710.9 | 2479.2 ± 763.8                 | 2409.6 ± 583.6                         | 0.442   |
| Smoker/Non-smoker² | 175/119     | 112/85                          | 63/34                                  | 0.184   |

Values are means ± standard deviation. Subjects with polymorphism were compared with subjects without polymorphism. Basically, we used Student’s t-test. As to variables with mark, we analyzed as follow.

* : Wilcoxon rank-sum test.

* : Variable was log transformed, and the Student’s t-test was used. Data is pre-log transformed.

² : P<0.05 for Student’s t-test.

Table 2. The mean waist circumference and body mass index values in each quartile, according to the energy intake.

| Energy intake | 1st quartile (-1515 kcal/day) | 2nd quartile (1516-1795 kcal/day) | 3rd quartile (1796-2131 kcal/day) | 4th quartile (2132+ kcal/day) | trend test |
|---------------|--------------------------------|-----------------------------------|-----------------------------------|------------------------------|------------|
| n             | 73                             | 74                                | 74                                | 74                           |            |
| Waist circumference (cm) | 82.6 ± 9.53                   | 82.9 ± 8.33                      | 84.9 ± 9.02                       | 85.2 ± 10.1                 | 0.043      |
| Body mass index (kg/m²)    | 22.6 ± 3.28                    | 23.2 ± 3.24                      | 23.6 ± 3.33                       | 23.8 ± 3.24                 | 0.024      |

Values are means ± standard deviation. Subjects in the 2nd, 3rd, and 4th quartile were compared with subjects in the 1st quartile.

We used Student’s t-test and trend test.

* : P<0.05 for Student’s t-test.
Table 3. The ratio of the obese (waist circumference 85+ cm) to the non-obese (waist circumference less than 85 cm) by the ADRB3 polymorphism.

| ADRB3 genotype | without polymorphism (Trp/Trp) | with polymorphism (Trp/Arg or Arg/Arg) | both |
|----------------|-----------------------------|---------------------------------|------|
| 1st quartile   |                             |                                 |      |
| n (the obese/the non-obese) | 24/26                        | 8/15                            | 32/41|
| the ratio of the obese to the non-obese | 0.92                          | 0.53                           | 0.78 |
| 2nd quartile   |                             |                                 |      |
| n (the obese/the non-obese) | 24/21                        | 7/22                            | 31/43|
| the ratio of the obese to the non-obese | 1.14                          | 0.32                           | 0.72 |
| 3rd quartile   |                             |                                 |      |
| n (the obese/the non-obese) | 31/23                        | 9/10                            | 40/33|
| the ratio of the obese to the non-obese | 1.35                          | 0.90                           | 1.21 |
| 4th quartile   |                             |                                 |      |
| n (the obese/the non-obese) | 21/27                        | 19/7                            | 40/34|
| the ratio of the obese to the non-obese | 0.78                          | 2.71                           | 1.18 |
| all subjects   |                             |                                 |      |
| n (the obese/the non-obese) | 100/97                       | 43/54                           | 143/151|
| the ratio of the obese to the non-obese | 1.03                          | 0.80                           | 0.95 |

The ratio of the obese to the non-obese in the group with the polymorphism was compared with that in the group without the polymorphism in each quartile. We used $\chi^2$ test.

* : P<0.05.

Table 4. The ratio of the obese (body mass index 25+ kg/m$^2$) to the non-obese (body mass index less than 25 kg/m$^2$) by the ADRB3 polymorphism.

| ADRB3 genotype | without polymorphism (Trp/Trp) | with polymorphism (Trp/Arg or Arg/Arg) | both |
|----------------|-----------------------------|---------------------------------|------|
| 1st quartile   |                             |                                 |      |
| n (the obese/the non-obese) | 12/38                        | 5/18                            | 17/56|
| the ratio of the obese to the non-obese | 0.32                          | 0.28                           | 0.30 |
| 2nd quartile   |                             |                                 |      |
| n (the obese/the non-obese) | 14/31                        | 6/23                            | 20/54|
| the ratio of the obese to the non-obese | 0.45                          | 0.26                           | 0.37 |
| 3rd quartile   |                             |                                 |      |
| n (the obese/the non-obese) | 17/38                        | 6/13                            | 23/51|
| the ratio of the obese to the non-obese | 0.45                          | 0.46                           | 0.45 |
| 4th quartile   |                             |                                 |      |
| n (the obese/the non-obese) | 16/32                        | 11/15                           | 27/47|
| the ratio of the obese to the non-obese | 0.50                          | 0.73                           | 0.57 |
| all subjects   |                             |                                 |      |
| n (the obese/the non-obese) | 59/139                       | 28/69                           | 87/208|
| the ratio of the obese to the non-obese | 0.42                          | 0.41                           | 0.42 |

The ratio of the obese to the non-obese in the group with the polymorphism was compared with that in the group without the polymorphism in each quartile. We used $\chi^2$ test.
In this study, we classified the subjects into quartiles according to energy intake based on the replies to the FFQ. The values for energy intake based on the FFQ in this study were slightly lower than the National Nutrition Survey in 2002, which were based on diet records. The discrepancy is thought to be due to a failure to list all food items consumed by the subjects in the period due to the limitation on the number of food items listed in the FFQ. The FFQ has been reported to underestimate the absolute level of consumption of nutrients and food groups compared to diet records. However, it has been also reported that while the FFQ underestimates the absolute levels of consumption of nutrients and food groups, it is reasonably valid in ranking subjects and classifying them into quintiles according to the consumption of many nutrients and food groups. Furthermore, the percentages of complete agreement, adjacent agreement, and complete disagreement according to tertile classification of daily energy intake and the presence of the polymorphism of ADRB3 indicate that the combination of proper energy intake and the presence of the polymorphism of ADRB3 makes this a risk factor for obesity. Moreover, these results indicate that the combination of proper energy intake and the presence of the polymorphism of ADRB3 may tend to reduce the risk of obesity. The hypothesis that the presence of the polymorphism of ADRB3 alone does not affect the risk of obesity is supported by the finding that when the subjects were classified into two groups according to presence of the polymorphism, no significant difference in waist circumference or BMI was seen between the subjects with and without the polymorphism (84.1 vs 83.5, 9.19 vs 9.57, and 23.4 vs 23.2, respectively) (Table 1).

The results of the multiple logistic regression analysis showing that the presence of the polymorphism of ADRB3 increases the risk of obesity in the 4th quartile alone (Table 5) also suggests interaction between high energy intake and the polymorphism of ADRB3.

A study comparing BMI, waist circumference, and waist-hip ratio (WHR) in regard to their respective associations with accumulation of abdominal visceral adipose tissue showed that the highest significant positive correlation was between waist circumference and abdominal visceral adipose tissue area measured by computed tomography in both men and women (r=0.77 and 0.87, respectively). When obesity was defined according to waist circumference not BMI in the present study, the interaction between the polymorphism of ADRB3 and high energy intake was found to increase the risk of obesity. This finding indicates that the polymorphism of ADRB3 is associated with visceral-fat obesity, which is supported by the finding that in humans ADRB3 is predominantly expressed in visceral fat. The polymorphism of ADRB3 has previously been reported to be associated with visceral-fat obesity, and the results of the present study do not contradict these reports.

Adipose tissue functions as a secretory tissue producing various adipocytokines including leptin, tumor necrosis factor-alpha (TNF-α), plasminogen activator inhibitor type 1 (PAI-1), and adiponectin. It is reported that adiponectin has anti-diabetic, anti-atherogenic, and anti-inflammatory biofunctions, and that the plasma levels of adiponectin decreased with the accumulation of visceral adipose tissue. It is also reported that intra-abdominal fat area was significantly associated with all of the metabolic syndrome criteria, including blood pressure, waist circumference, HDL cholesterol, triglyceride level, and fasting plasma glucose level, independent of insulin sensitivity and subcutaneous fat area. In addition, intra-abdominal fat area was independently associated with development of metabolic syndrome (adjusted OR=2.43, 95% CI=1.33-4.47). Moreover, in the study based on 11 prospective European cohort studies involving 6156 men and 5356 women without diabetes, the overall hazard ratios for all-cause and cardiovascular disease mortality in subjects with the

**Table 5. The multiple logistic regression analysis on obesity defined as waist circumference 85+ cm in the 4th quartile.**

| Explanatory variables | Adjusted odds ratio (95% confidence interval) |
|-----------------------|---------------------------------------------|
| Presence of the polymorphism of ADRB3 | 3.37 (1.12-10.16) |
| Age (per year) | 1.04 (1.00-1.08) |
| Smoking (smoker/non-smoker) | 0.48 (0.17-1.37) |
| Physical activity (per 1000 METs* minutes) | 0.76 (0.40-1.46) |

Presence of the polymorphism of ADRB3, age, smoking, and physical activity were considered as variables.
metabolic syndrome compared with those without the syndrome were 1.44 (95% CI=1.17-1.84) and 2.26 (95% CI=1.61-3.17) in men and 1.38 (95% CI=1.02-1.87) and 2.78 (95% CI=1.57-4.94) in women after adjustment for age, blood cholesterol levels, and smoking. Therefore, it is possible that prevention or treatment of visceral fat obesity, which is said to be associated with the polymorphism of ADRB3, could lead to reduced mortality associated with the metabolic syndrome.

The results of the present study demonstrated that the polymorphism of ADRB3 alone does not increase the risk of obesity and that the environmental factor of high energy intake interacts with the polymorphism and leads to the significant increase in risk of obesity. This indicates the possibility that subjects with the Trp64Arg polymorphism can avoid the increase in the risk of obesity by proper energy intake control. Therefore, the Trp64Arg polymorphism may be a factor that we should take into consideration when we aim to tailor-made prevention or treatment of obesity. However, the findings that no significant difference in waist circumference or BMI was seen between the subjects with and without the polymorphism indicate that the effect of the polymorphism in the development of obesity is rather small and that it may be difficult to carry out tailor-made prevention or treatment of obesity based on genotyping of the Trp64Arg polymorphism of ADRB3 alone. Further studies investigating the interaction between the Trp64Arg polymorphism of ADRB3 and other polymorphisms involved in the development of obesity, will be needed.

We are grateful to Mrs. Maria Kanetake for her support in the statistical analysis and to Mr. Shugo Tohyama for their assistance in this research project.

References

1. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-43.
2. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987; 36: 54-9.
3. Kanai H, Matsuzawa Y, Kotani K, Keno Y, Kobatake T, Nagai Y, et al. Close correlation of intra-abdominal fat accumulation to hypertension in obese women. Hypertension 1990; 16: 484-90.
4. Yamashita S, Nakamura T, Shimomura I, Nishida M, Yoshida S, Kotani K, et al. Insulin resistance and body fat distribution. Diabetes Care 1996; 19: 287-91.
5. Snyder EE, Walts B, Perusse L, Chagnon YC, Weisnagel SJ, Rankinen T, et al. The human obesity gene map: the 2003 update. Obes Res 2004; 12: 369-439.
6. Krief S, Lonqqvist F, Raimbault S, Baude B, Van Sprosen A, Arner P, et al. Tissue distribution of beta 3-adrenergic receptor mRNA in man. J Clin Invest 1993; 91: 344-9.
7. Emorine LJ, Marullo S, Briend-Sutten MM, Patey G, Tate K, Delavier-Klutcho C, et al. Molecular characterization of the human beta 3-adrenergic receptor. Science 1989; 245: 1118-21.
8. Walston J, Silver K, Bogardus C, Knowler WC, Celi FS, Austin S, et al. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med 1995; 333: 343-7.
9. Clement K, Vaisse C, Manning BS, Basdevant A, Guy-Grand B, Ruiz J, et al. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 1995; 333: 352-4.
10. Widén E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC. Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 1995; 333: 348-51.
11. Arner P, Hoffstedt J. Adrenoceptor genes in human obesity. J Intern Med 1999; 245: 667-72.
12. Yoshida T, Sakane N, Umekawa T, Sakai M, Takahashi T, Kondo M. Mutation of beta 3-adrenergic-receptor gene and response to treatment of obesity. Lancet 1995; 346: 1433-4.
13. Sakane N, Yoshida T, Umekawa T, Kondo M, Sakai Y, Takahashi T. Beta 3-adrenergic-receptor polymorphism: a genetic marker for visceral fat obesity and insulin resistance syndrome. Diabetologia 1997; 40: 200-4.
14. Endo K, Yanagi H, Hirano C, Hamaguchi H, Tsuchiya S, Tomura S. Association of Trp64Arg polymorphism of the beta 3-adrenergic receptor gene and no association of Gln223Arg polymorphism of the leptin receptor gene in Japanese schoolchildren with obesity. Int J Obes Relat Metab Disord 2000; 24: 443-9.
15. Kadowaki H, Yasuda K, Iwamoto K, Otabe S, Shimokawa K, Silver K, et al. A mutation in beta 3-adrenergic receptor gene is associated with obesity and hyperinsulinemia in Japanese subjects. Biochem Biophys Res Commun 1995; 215: 555-60.
16. Fujisawa T, Ikegami H, Kawaguchi Y, Ogihara T. Meta-analysis of the association of Trp64Arg polymorphism of beta 3-adrenergic receptor gene with body mass index. J Clin Endocrinol Metab 1998; 83: 2441-4.
17. Examination Committee of Criteria for ‘Obesity Disease’ in Japan, Japan Society for the Study of Obesity. New criteria for ‘obesity disease’ in Japan. Circ J 2002; 66: 978-92.
18. Larsson B, Bengtsson C, Björnortorp P, Lapidus L, Svärdsudd K, et al. Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction? The study of men born in 1913 and the study of women, Göteborg, Sweden. Am J Epidemiol 1992; 135: 266-73.
19. Takahasi K, Yoshimura Y, Kaimoto T, Kunii D, Komatsu T, Miyaki K, et al.
Yamamoto S. Validation of a food frequency questionnaire based on food groups for estimating individual nutrient intake. Jpn J Nutr 2001; 59: 221-32. (in Japanese)

20. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000; 32 (9 Suppl): S498-S516.

21. Kuppuswamy MN, Hoffmann JW, Kasper CK, Spitzer SG, Groce SL, Bajaj SP. Single nucleotide primer extension to detect genetic disease: experimental application to hemophilia B (factor Ⅷ) and cystic fibrosis genes. Proc Natl Acad Sci USA 1991; 88: 1143-7.

22. Ministry of Health, Labour and Welfare, Japan. The National Nutrition Survey in Japan, 2002. Daiichi-Syuppan: Tokyo, 2004. (in Japanese)

23. Tsubono Y, Kobayashi M, Sasaki S, Tsugane S. Validity and reproducibility of a self-administered food frequency questionnaire used in the baseline survey of the JPHC Study Cohort I. J Epidemiol 2003; 13(1 Suppl): S125-S133.

24. Ogawa K, Tsubono Y, Nishino Y, Watanabe Y, Ohkubo T, Watanabe T, et al. Validation of a food-frequency questionnaire for cohort studies in rural Japan. Public Health Nutr 2003; 6: 147-57.

25. Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994; 73: 460-8.

26. Kim-Motoyama H, Yasuda K, Yamaguchi T, Yamada N, Katakura T, Shuldiner AR, et al. A mutation of the beta 3-adrenergic receptor is associated with visceral obesity but decreased serum triglyceride. Diabetologia 1997; 40: 469-72.

27. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, et al. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1: 1155-61.

28. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259:87-91.

29. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2:800-3.

30. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adipose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221:286-9.

31. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002; 13: 51-9.

32. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through cAMP-dependent pathway. Circulation 2000; 102: 1296-301.

33. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96: 1723-32.

34. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46: 459-69.

35. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.

36. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004; 53: 2087-94.

37. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066-76.